Mechanism of Novel FDA Approved Nonhormone Treatment Option for Vasomotor Symptoms Explained
MenopauseSociety MenopauseSociety
6.06K subscribers
2,848 views
19

 Published On May 18, 2023

Dr. Susan Reed discusses the first neurokinin 3 (NK3) receptor antagonist approved by FDA to treat moderate to severe hot flashes that works by binding to and blocking the activities of the NK3 receptor, the brain’s thermoregulator. (www.menopause.org)

show more

Share/Embed